1. Home
  2. UAMY vs NTLA Comparison

UAMY vs NTLA Comparison

Compare UAMY & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United States Antimony Corporation

UAMY

United States Antimony Corporation

HOLD

Current Price

$9.04

Market Cap

1.4B

Sector

Industrials

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$14.09

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UAMY
NTLA
Founded
1968
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.5B
IPO Year
1997
2016

Fundamental Metrics

Financial Performance
Metric
UAMY
NTLA
Price
$9.04
$14.09
Analyst Decision
Strong Buy
Buy
Analyst Count
5
23
Target Price
$9.44
$20.02
AVG Volume (30 Days)
12.5M
5.7M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
$39,257,708.00
$67,671,000.00
Revenue This Year
$219.89
N/A
Revenue Next Year
$104.28
$62.75
P/E Ratio
N/A
N/A
Revenue Growth
162.80
16.92
52 Week Low
$1.94
$6.92
52 Week High
$19.71
$28.24

Technical Indicators

Market Signals
Indicator
UAMY
NTLA
Relative Strength Index (RSI) 46.69 55.93
Support Level $7.45 $11.55
Resistance Level $11.15 $15.53
Average True Range (ATR) 0.76 0.98
MACD -0.06 0.10
Stochastic Oscillator 45.67 62.24

Price Performance

Historical Comparison
UAMY
NTLA

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the Domestic, Canada, and Mexico, of which the vast majority of its revenue comes from the Domestic.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: